

PRESS RELEASE

Date 2 May 2019
Contact Investor Relations: Felix Burkhard, CFO, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject 2019 Annual General Meeting of Galenica Ltd.

2nd Annual General Meeting of Galenica Ltd.: Daniela Bosshardt-Hengartner elected new Chairwoman of the Board of Directors

At the Annual General Meeting of Galenica Ltd. on 2 May 2019, Daniela Bosshardt-Hengartner was elected the new Chairwoman of the Board of Directors. After 17 years with the company, Jörg Kneubühler, former Chairman of the Board of Directors, decided not to stand for re-election in order to focus on other projects. Shareholders also elected Markus R. Neuhaus as a new member of the Board of Directors and approved the 3% increase in dividend to CHF 1.70 per share.

The second Annual General Meeting of Galenica Ltd. was attended by 369 shareholders representing a total of 72.7% of the registered voting shares of Galenica Ltd.

Daniela Bosshardt-Hengartner newly elected Chairwoman of the Board of Directors

The Annual General Meeting elected Daniela Bosshardt-Hengartner as the new Chairwoman of the Board of Directors of the Galenica Group, thereby following the proposal submitted by the Board of Directors. She has a Federal Diploma in Pharmacy from the Federal Institute of Technology (ETH) Zurich as well as sound financial expertise and a wealth of experience as a management consultant. Combined with her previous years of service as a member of the Board of Directors of Galenica, but also of other companies, Daniela Bosshardt-Hengartner is the ideal fit for the role of Chairwoman of the Board of Directors.

Departure of Jörg Kneubühler

Jörg Kneubühler, who had chaired the Galenica Group since the initial public offering (IPO) in April 2017 and had worked at Galenica in various roles for 17 years, decided to step down from his position as Chairman of the Board of Directors at the Annual General Meeting, and not to stand for re-election as a member of the Board of Directors. After successfully leading the Galenica Group to independence following the two years after the IPO, he now wants to devote his time to new projects. Jörg Kneubühler was thanked for his considerable commitment and given a duly farewell at the Annual General Meeting.

Markus R. Neuhaus newly elected to the Board of Directors

The Annual General Meeting also elected Markus R. Neuhaus as a new member of the Board of Directors. Markus R. Neuhaus, who has a PhD in law and is a certified tax expert, also has many years of consulting experience in the areas of corporate strategy and governance as well as an extensive network in the worlds of business and politics in Switzerland.

Approval of all proposals submitted by the Board of Directors

The shareholders also voted in favour of all other proposals put forward by the Board of Directors on the items on the agenda: The Annual General Meeting approved the Management Report (Annual Report 2018) and the 2018 Annual Financial Statements of Galenica Ltd. as well as the Consolidated Financial Statements of the Galenica Group for 2018 and discharged the members of the Board of Directors and the Corporate Executive Committee from liability for their activities in financial year 2018.

Dividend distribution in the planned amount

The Annual General Meeting also approved the dividend of CHF 1.70 per share proposed by the Board of Directors, which is 3% higher than the previous year. As planned, this corresponds to an expected distribution of CHF 83.8 million. Dividends will be paid to shareholders free from withholding tax from the capital contribution reserves on 8 May 2019.

Total remuneration for financial year 2020 and the 2018 Remuneration Report approved

The proposed binding maximum total remuneration for 2020 for members of the Board of Directors and Corporate Executive Committee was very clearly approved by the shareholders. In a consultative vote, the shareholders also endorsed the 2018 Remuneration Report.

Amendment to Article 3a, paragraph 1 of the Articles of Association (authorised capital)

The Board of Directors proposal to renew the authorisation to increase the authorised capital by a maximum amount of CHF 500,000 and to extend the period of authorisation until 2 May 2021 was also approved by the shareholders.

Re-elections to the Board of Directors

The following members of the Board of Directors were re-elected for a term of office lasting one year: Daniela Bosshardt-Hengartner, Prof. Dr. Michel Burnier, Fritz Hirsbrunner, Bertrand Jungo, Dr. Philippe Nussbaumer and Dr. Andreas Walde. Bertrand Jungo will take over the Vice-Presidency.

Re-elections and election to the Remuneration Committee

Fritz Hirsbrunner and Prof. Dr. Michel Burnier were re-elected to the Remuneration Committee for a term of office lasting one year. Due to her new role as Chairwoman of the Board of Directors, Daniela Bosshardt-Hengartner did not stand for re-election. The shareholders followed the proposal of the Board of Directors and elected Dr. Andreas Walde as a new member of the Remuneration Committee.

Dates for the diary

2019

Galenica Investor Day 2019:	25 June 2019
2019 half-year results of the Galenica Group:	6 August 2019

2020

2019 sales of the Galenica Group:	21 January 2020
2019 annual results of the Galenica Group:	10 March 2020
Annual General Meeting of Galenica Ltd.:	19 May 2020

Date 2 May 2019
Page 3/3
Subject 2019 Annual General Meeting of Galenica Ltd.

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Galenica is the leading fully integrated healthcare provider in Switzerland. With over 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of pre-wholesale and wholesale distribution services as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning Galenica can be found at www.galenica.com